Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    tanezumab
Show Display Options
Rank Status Study
1 Terminated Extension Study Of Tanezumab In Osteoarthritis
Condition: Osteoarthritis
Intervention: Biological: tanezumab
2 Completed Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected
Conditions: Osteoarthritis Pain;   Chronic Low Back Pain;   Pain Due to Interstitial Cystitis
Interventions: Other: placebo;   Biological: tanezumab
3 Terminated Long Term Safety Study of Tanezumab in Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg;   Biological: Tanezumab 10 mg
4 Terminated A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy
Condition: Diabetic Peripheral Neuropathy
Interventions: Biological: Tanezumab;   Biological: placebo
5 Completed A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
Conditions: Neoplasm Metastasis;   Palliative Care
Interventions: Drug: Tanezumab 10 mg IV;   Drug: IV Placebo for tanezumab
6 Recruiting Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
Conditions: Osteoarthritis, Knee;   Osteoarthritis, Hip
Interventions: Other: Placebo;   Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 2.5mg/5mg
7 Terminated Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis
Condition: Chronic Pancreatitis
Interventions: Biological: Tanezumab;   Other: Placebo
8 Recruiting Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.
Conditions: Neoplasm Metastasis;   Musculoskeletal Pain
Intervention: Drug: Tanezumab
9 Recruiting Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
Conditions: Chronic Pain;   Osteoarthritis, Hip;   Osteoarthritis, Knee
Interventions: Drug: NSAID;   Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 5 mg
10 Terminated Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis
Condition: Osteoarthritis
Intervention: Biological: Tanezumab
11 Terminated A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
Condition: Endometriosis
Interventions: Biological: Tanezumab;   Drug: Placebo
12 Completed Tanezumab in Osteoarthritis Of The Hip
Conditions: Arthritis;   Osteoarthritis;   Osteoarthritis, Hip
Interventions: Biological: tanezumab;   Biological: Placebo
13 Terminated A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
Conditions: Osteoarthritis, Knee;   Osteoarthritis, Hip
Interventions: Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 5 mg;   Biological: Tanezumab 10 mg
14 Terminated Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip
Condition: Osteoarthritis
Interventions: Biological: tanezumab;   Drug: diclofenac;   Other: IV placebo
15 Terminated Tanezumab and Nerve Function In Arthritis Patients
Condition: Osteoarthritis
Interventions: Biological: tanezumab;   Other: Placebo
16 Recruiting Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
Conditions: Osteoarthritis,Knee;   Osteoarthritis, Hip
Interventions: Drug: Tanezumab;   Drug: Placebo
17 Recruiting Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Celecoxib;   Biological: Tanezumab 5 mg;   Biological: Tanezumab 10 mg;   Drug: Placebo for celecoxib;   Biological: Placebo for tanezumab
18 Completed A Study of Tanezumab in Adults With Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV;   Drug: Placebo for naproxen;   Biological: Tanezumab 10 mg IV;   Biological: Tanezumab 5 mg IV;   Biological: Placebo for tanezumab;   Drug: Naproxen
19 Completed An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
Condition: Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions: Drug: Tanezumab;   Drug: Placebo
20 Completed Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
Condition: Healthy Volunteers
Intervention: Biological: tanezumab

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.